NEW YORK (Reuters Health)—Vitamin D-metabolite ratio (VMR) may be a better marker of bone health than 25(OH)D (25-hydroxyvitamin D), a new study suggests. “The parameter that’s currently used to assess vitamin D status, 25(OH)D, is a flawed measure because it doesn’t consistently associate with important bone outcomes like hip fractures,” Dr. Charles Ginsberg of Veterans…
IV Saline Shortage Update
Early last month we informed you about the IV saline solution shortage that was exacerbated by Hurricane Maria’s impact on Baxter’s manufacturing facility in Puerto Rico. Since then, the ACR advocacy team has been working with the Food and Drug Administration (FDA) in its ongoing efforts to resolve the fluid shortage. Currently, the FDA has…
Drug Industry Group Sues to Stop California Drug Price Law
(Reuters)—The trade group representing U.S. drugmakers on Friday said it has a filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices. The Pharmaceutical Research and Manufacturers of America (PhRMA), in a statement, said it filed litigation in the U.S. District Court for the Eastern District of California…
Opioid Painkiller Prescriptions May Run in Families
(Reuters Health)—When one person in a household gets prescribed opioids, the other people who live with them are more likely to get their own prescriptions for these narcotic painkillers, a U.S. study suggests. Researchers examined data on about 12.6 million people living in a household where someone was prescribed opioids and 6.4 million individuals in…
Limbrel Linked to Possible Fatal Adverse Events
The FDA is investigating serious and potentially fatal side effects associated with Limbrel, which is designed to manage metabolic processes in patients with osteoarthritis…
Upadacitinib Promising for RA in Phase 3 Study
In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…
European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…
Bisphosphonate Drug Holiday & Hip Fracture Risk
New research found women on bisphosphonate therapy who take a drug holiday experience a higher rate of hip fracture…
Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…
Biosimilars Great Debate: To Switch or Not?
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 120
- Next Page »